CSPC Pharmaceutical Group Limited Share Price and Company Fundamentals
Last traded: Today at 2:52 AM
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
|Industry / Sector||Drug Manufacturers—General / Healthcare|
|Full time employees||24746|
|Mailing address||No. 226 Huanghe Street Shijiazhuang 050035 China|
|Phone / Fax||86 31 1870 37015 / 86 31 1870 39608|
5Y Avg. yield
CSPC Pharmaceutical Group Limited paid $0.15 dividend and the ex-dividend date was 31 May 2022.The dividend payout ratio is 29.93%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.1093 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
1093's forward dividend amount is $0.18 and the forward dividend yield is 2.32%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of May 2022, following are the company executives and directors listed on CSPC Pharmaceutical Group Limited.
|Mr. Dongchen Cai||Exec. Chairman & CEO||67||1.98M|
|Mr. Cuilong Zhang||Vice-Chairman & Rotating CEO||51||1.36M|
|Mr. Chunlei Li||Exec. Director & Chief Scientist||45||741.26k|
|Mr. Kin Man Chak||Exec. Director||55||746.19k|
|Mr. Weidong Pan||Exec. Director||51||747.24k|
|Mr. Huaiyu Wang||Exec. Director||58||740.66k|
|Mr. Zhenguo Wang||Exec. Director||51||740.66k|
|Dr. Qingxi Wang||Exec. Director||55||259.64k|
|Dr. Hao Jiang||Exec. Director||38||747.39k|
|Mr. Jinxu Wang||Sr. VP||50|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of CSPC Pharmaceutical Group Limited is and its enterprise value is .
The 1093's stocks Beta value is 0.65 making it 35% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
CSPC Pharmaceutical Group Limited (HKEX:1093) Frequently Asked Questions
1. What is CSPC Pharmaceutical Group Limited's Stock Symbol?
CSPC Pharmaceutical Group Limited trades on HKEX under the ticker symbol "1093".
2. What is CSPC Pharmaceutical Group Limited's stock price today?
One share of 1093 stock can currently be purchased for approximately $7.74.
3. How can I contact CSPC Pharmaceutical Group Limited?
CSPC Pharmaceutical Group Limited's mailing address is No. 226 Huanghe Street Shijiazhuang 050035 China. The company can be reached via phone at 86 31 1870 37015.
4. What is CSPC Pharmaceutical Group Limited's official website?
The official website of CSPC Pharmaceutical Group Limited is https://www.cspc.com.hk.